{
    "organizations": [],
    "uuid": "77e2726025a47485448cf3c0e0431d574c14e265",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ra-pharmaceuticals-q1-loss-per-sha/brief-ra-pharmaceuticals-q1-loss-per-share-0-61-idUSASC0A16F",
    "ord_in_thread": 0,
    "title": "BRIEF-Ra Pharmaceuticals Q1 Loss Per Share $0.61",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 9 (Reuters) - Ra Pharmaceuticals Inc:\n* RA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE\n* Q1 LOSS PER SHARE $0.61 * Q1 EARNINGS PER SHARE VIEW $-0.56 â€” THOMSON REUTERS I/B/E/S\n* EXPECTS THAT ITS CASH AND CASH EQUIVALENTS AT MARCH 31, 2018 WILL BE SUFFICIENT TO FUND OPERATIONS THROUGH END OF 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-10T04:37:00.000+03:00",
    "crawled": "2018-05-10T17:25:25.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "ra",
        "pharmaceutical",
        "inc",
        "ra",
        "pharmaceutical",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "provides",
        "corporate",
        "update",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "expects",
        "cash",
        "cash",
        "equivalent",
        "march",
        "sufficient",
        "fund",
        "operation",
        "end",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}